ADCY5
Identifiers
Aliases	ADCY5, AC5, FDFM, adenylate cyclase 5, DSKOD
External IDs	OMIM:600293;MGI:99673;HomoloGene:11213;GeneCards:ADCY5;OMA:ADCY5 - orthologs
Gene location (Human) Chr. Chromosome 3 (human)[1] Band 3q21.1 Start 123,282,296bp[1] End 123,449,090bp[1]
Gene location (Mouse) Chr. Chromosome 16 (mouse)[2] Band 16|16 B3 Start 34,975,247bp[2] End 35,126,108bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in apex of heart gastric mucosa right coronary artery popliteal artery tibial arteries right auricle of heart left ventricle putamen nucleus accumbens cardiac muscle tissue of right atrium Top expressed in olfactory tubercle nucleus accumbens ascending aorta globus pallidus superior frontal gyrus nucleus of stria terminalis aortic valve lateral septal nucleus temporal lobe amygdala More reference expression data BioGPS More reference expression data
Gene ontology Molecular function nucleotide binding adenylate cyclase binding metal ion binding lyase activity protein heterodimerization activity adenylate cyclase activity phosphorus-oxygen lyase activity ATP binding scaffold protein binding guanylate cyclase activity Cellular component integral component of membrane cell projection membrane plasma membrane cilium intermediate filament cytoskeleton guanylate cyclase complex, soluble integral component of plasma membrane Biological process cAMP biosynthetic process G protein-coupled adenosine receptor signaling pathway adenylate cyclase-activating dopamine receptor signaling pathway regulation of insulin secretion involved in cellular response to glucose stimulus intracellular signal transduction cellular response to forskolin adenylate cyclase-activating G protein-coupled receptor signaling pathway locomotory behavior neuromuscular process controlling balance positive regulation of cytosolic calcium ion concentration cellular response to glucagon stimulus cyclic nucleotide biosynthetic process adenylate cyclase-inhibiting dopamine receptor signaling pathway renal water homeostasis cGMP biosynthetic process adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway G protein-coupled receptor signaling pathway activation of adenylate cyclase activity activation of protein kinase A activity Sources:Amigo /QuickGO
Orthologs Species Human Mouse Entrez 111 224129 Ensembl ENSG00000173175 ENSMUSG00000022840 UniProt O95622 P84309 RefSeq (mRNA) NM_001199642 NM_183357 NM_001378259 NM_001012765 RefSeq (protein) NP_001186571 NP_899200 NP_001365188 NP_001012783 Location (UCSC) Chr 3: 123.28 – 123.45 Mb Chr 16: 34.98 – 35.13 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Adenylyl cyclase type 5 is anenzyme that in humans is encoded by theADCY5gene.^[5][6]

The humanADCY5 gene is located on the long arm of chromosome 3 and codes for the enzyme Adenylyl Cyclase 5 (AC5). This membrane protein has catalytic activity to convertadenosine triphosphate (ATP) intocyclic adenosine monophosphate (cAMP). In the brain, this enzyme is highly expressed inmedium spiny neurons (MSNs) in thestriatum. It is also found in non-neuronal cells such as cardiomyocytes and pancreatic islets. AC5 plays a role in several physiological processes including the modulation of neuronal activity particularly in the striatum, thus variants inADCY5 gene typically lead tomovement disorders.

AC5 is encoded by theADCY5 gene, located on the long arm of chromosome 3. The AC5 protein is composed of an intracytoplasmic N-terminal domain, a first membrane subdomain of 6 transmembrane segments, a first catalytic subdomain (C1a), a regulatory domain (C1b), a second membrane subdomain of 6 transmembrane segments, and a second catalytic subdomain (C2a). In contrast to otherACs, AC5 doesn't have a complete C-terminal regulatory domain (C2b). In the cytoplasm, the 2 catalytic subdomains associate to form the catalytic domain, binding ATP and converting it intocAMP. The 2 membrane subdomains are associated to form a single bundle in the plasmic membrane.^[7] The transmembrane domain is prolonged by 2 cytoplasmic helices (H1 and H2) forming acoiled-coil domain which separates the core catalytic domain from the membrane. The conformation of the C1b regulatory and coiled-coil domains as well as their association with the various subunits of the G proteins change the dynamic conformation of the 2 catalytic subdomains and impact the catalytic activity of AC5. The N-terminal domain may participate in regulation by G proteins;^[8][9] however, its structural organization is only partly solved.

The mammalianadenylyl cyclase family comprises nine membrane adenylyl cyclases (mACs, AC1-9), and one soluble adenylyl cyclase (sAC, AC10). As an adenylyl cyclase, AC5 catalyses the production of the second messengercAMP from ATP, under the regulation ofG proteins.^[10][11] The level of cellularcAMP controls the activity ofprotein kinase A (PKA), which phosphorylates target proteins. Upon phosphorylation, these effectors allow the cellular response to stimulation ofG protein-coupled receptors (GPCR). However, AC5 differs from other mACs by its sequence and length, its expression pattern and its regulation.AC5 has been identified as the primaryAC isoform expressed inMSNs.^[12] The striatum controls movement via a subtle balance between the activity of two types of MSNs: the striato-nigral MSNs of the direct pathway that facilitate movement execution and the striato-pallidal MSNs of the indirect pathway that inhibit movement execution. The synthesis ofcAMP by AC5 in MSNs is finely regulated byG protein-coupled receptors. AC5 is activated by the Gαolf protein (encoded by theGNAL gene) downstream of theD1 dopamine receptor (D1R) in the direct pathway and theadenosine A_2A receptor (A_2AR) in the indirect pathway, while it is inhibited by Gαi/o downstream of theD2 dopamine receptors (D2R) in the indirect pathway and theadenosine A₁ receptor (A₁R) in the direct pathway. cAMP levels in direct/indirect MSNs are critical for the activation of their target neurons, and thus facilitation or inhibition of movement.

In MSNs, AC5 associates with the heterotrimeric protein G containingGαolf,Gβ2 andGγ7.^[13] In vitro, AC5 can also interact withGβ1 andGγ2 through its N-terminal domain. AC5 has been shown tointeract withRGS2.^[14]

Mixed movement disorders linked toADCY5 (MxMD-ADCY5) is a rare childhood-onsethyperkinetic disease due to pathogenic variants in theADCY5 gene.

ADCY5-related movement disorder is named after the causative geneADCY5, found in 2012 via wholeexome sequencing.^[15] However, the first patient's description was made in 1967 as “paroxysmal choreoathetosis”.^[16] This case and her family history were reappraised when her daughter started to have similar manifestations, then described as “familial dyskinesia with facial myokymia”.^[17] This disease is presently referred to as MxMD-ADCY5 since the phenotypic spectrum has been more extensively studied.^[18] Indeed, the clinical spectrum is very broad and is typically characterized by a variable combination of permanent and paroxysmal hyperkinetic movements such asmyoclonus,chorea,tremor and/ordystonia.^[19] These symptoms can be more or less severe but, in most cases, hamper the quality of life of patients. The occurrence of paroxysmal nocturnaldyskinesias and the presence of perioral twitches are particularly suggestive of the diagnosis. These dyskinesias are sometimes associated with other symptoms such as axialhypotonia, speech disturbance, oculomotor signs,pyramidal syndrome, developmental delay,psychiatric disorders orintellectual disability.^[20] Likewise, a few patients have been reported withheart failure, raising the possibility of cardiac involvement.^[21]

MxMD-ADCY5 is most often transmitted in anautosomal dominant manner and more rarely autosomal recessive.^[22] The occurrence of somaticmosaicism^[18] is unexpectedly frequent in MxMD-ADCY5, with a less severe phenotype.^[19] The most described causal variant is the dominant mutation R418W situated in the coiled-coil domain of AC5. Most of the known variants are concentrated in the coiled-coil, catalytic (C1a and C2a) and regulatory (C1b) domains of AC5 suggesting a dysregulation of its enzymatic activity in patients.

The pathophysiology of this disease is based on a deregulation of the cAMP pathway in the striatum linked toADCY5 mutations, disrupting the balance between the direct and indirect pathways of movement control. In vitro functional studies have shown a gain of function for several dominant non-truncatingmutations altering cAMP production after G protein-coupled receptors stimulation compared to wildtype AC5.^[23][24] The pathophysiology of truncating and/or recessive variants is poorly known.

The pathophysiological mechanisms and preliminary evidence designate adenosine A_2A receptors’ antagonists, namelycaffeine,^[25]istradefylline andtheophylline, as potential first line treatments. Symptomatic treatment withbenzodiazepine might also be useful to some patients, especially to treat nighttimedyskinesia.^[19] In severe forms, bilateraldeep brain stimulation of theglobus pallidus internus (GPi-DBS) could be considered, with variable outcomes.^[26][27]

ADCY5 polymorphisms are also associated withneuropsychiatric andcentral nervous system disorders, notablyalcoholism,^[28]depression^[29] orautism.^[30]

ADCY5 seems to play a role in cardiac function and may be involved in bothlongevity andstress resistance. Indeed, mice with a complete depletion of ADCY5 live significantly longer than control littermates and are resistant to cardiac stress.^[31][32][33]

• HumanADCY5 genome location andADCY5 gene details page in theUCSC Genome Browser.
• ADCY5.org
• Paris Brain Institute :research on MxMD-ADCY5

• Genes on human chromosome 3
• EC 4.6.1

• Articles with short description
• Short description matches Wikidata